{"id":"https://openalex.org/W2504123697","doi":"https://doi.org/10.1158/1538-7445.am2016-2133","title":"Abstract 2133: Ending the endless acquired tyrosine kinase resistance mutations \u2014 Design of TPX-0005, a multi-target ALK/ROS1/TRK inhibitor with broad spectrum activity against wild-type and mutants including ALK G1202R, ROS1 G2032R and TRKA G595R","display_name":"Abstract 2133: Ending the endless acquired tyrosine kinase resistance mutations \u2014 Design of TPX-0005, a multi-target ALK/ROS1/TRK inhibitor with broad spectrum activity against wild-type and mutants including ALK G1202R, ROS1 G2032R and TRKA G595R","publication_year":2016,"publication_date":"2016-07-15","ids":{"openalex":"https://openalex.org/W2504123697","doi":"https://doi.org/10.1158/1538-7445.am2016-2133","mag":"2504123697"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2016-2133","doi":"https://doi.org/10.1158/1538-7445.am2016-2133","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2016-2133","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5045957422","display_name":"J. Jean Cui","orcid":"https://orcid.org/0009-0005-6287-1455","observed_orcids":["https://orcid.org/0009-0005-6287-1455"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"J. Jean Cui","raw_affiliation_strings":["TP Therapeutics. Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"TP Therapeutics. Inc., San Diego, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5032838816","display_name":"Evan Rogers","orcid":"https://orcid.org/0000-0002-7112-2289","observed_orcids":["https://orcid.org/0000-0002-7112-2289"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Evan Rogers","raw_affiliation_strings":["TP Therapeutics. Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"TP Therapeutics. Inc., San Diego, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110664862","display_name":"Dayong Zhai","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dayong Zhai","raw_affiliation_strings":["TP Therapeutics. Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"TP Therapeutics. Inc., San Diego, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Wei Deng","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Wei Deng","raw_affiliation_strings":["TP Therapeutics. Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"TP Therapeutics. Inc., San Diego, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100569830","display_name":"Zhongdong Huang","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Zhongdong Huang","raw_affiliation_strings":["TP Therapeutics. Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"TP Therapeutics. Inc., San Diego, CA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111738337","display_name":"Jeffrey Whitten","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jeffrey Whitten","raw_affiliation_strings":["TP Therapeutics. Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"TP Therapeutics. Inc., San Diego, CA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5022450416","display_name":"Yishan Li","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Yishan Li","raw_affiliation_strings":["TP Therapeutics. Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"TP Therapeutics. Inc., San Diego, CA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":7,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"76","issue":"14_Supplement","first_page":"2133","last_page":"2133"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10417","display_name":"Lung Cancer Treatments and Mutations","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2740","display_name":"Pulmonary and Respiratory Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13779","display_name":"Cancer Mechanisms and Therapy","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2734","display_name":"Pathology and Forensic Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10211","display_name":"Computational Drug Discovery Methods","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/1703","display_name":"Computational Theory and Mathematics"},"field":{"id":"https://openalex.org/fields/17","display_name":"Computer Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alk-inhibitors","display_name":"ALK inhibitors","score":0.7279999852180481},{"id":"https://openalex.org/keywords/ros1-inhibitors","display_name":"ROS1 inhibitors","score":0.9950000047683716},{"id":"https://openalex.org/keywords/trk-inhibitors","display_name":"TRK inhibitors","score":0.996999979019165},{"id":"https://openalex.org/keywords/multikinase-inhibitor","display_name":"multikinase inhibitor","score":0.6620000004768372},{"id":"https://openalex.org/keywords/acquired-drug-resistance","display_name":"acquired drug resistance","score":0.6510000228881836},{"id":"https://openalex.org/keywords/gatekeeper-mutations","display_name":"gatekeeper mutation","score":0.8349999785423279},{"id":"https://openalex.org/keywords/solvent-front-mutations","display_name":"solvent-front mutations","score":0.8090000152587891},{"id":"https://openalex.org/keywords/atp-binding-site","display_name":"ATP binding site","score":0.6510000228881836},{"id":"https://openalex.org/keywords/macrocycles","display_name":"macrocycles","score":0.5590000152587891},{"id":"https://openalex.org/keywords/crizotinib-resistance","display_name":"crizotinib resistance","score":0.7609999775886536},{"id":"https://openalex.org/keywords/kinase-inhibitor-design","display_name":"kinase inhibitor design","score":0.5009999871253967}],"concepts":[{"id":"https://openalex.org/C2779422266","wikidata":"https://www.wikidata.org/wiki/Q5186964","display_name":"Crizotinib","level":4,"score":0.7601627707481384},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.6237209439277649},{"id":"https://openalex.org/C117643217","wikidata":"https://www.wikidata.org/wiki/Q17824987","display_name":"Anaplastic lymphoma kinase","level":4,"score":0.5883344411849976},{"id":"https://openalex.org/C2778347629","wikidata":"https://www.wikidata.org/wiki/Q4652380","display_name":"ALK inhibitor","level":5,"score":0.5101190209388733},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.4090372920036316},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.4068748950958252},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.3689257800579071},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.320188045501709},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.194466233253479},{"id":"https://openalex.org/C2779634585","wikidata":"https://www.wikidata.org/wiki/Q1334541","display_name":"Pleural effusion","level":2,"score":0.0},{"id":"https://openalex.org/C141071460","wikidata":"https://www.wikidata.org/wiki/Q40821","display_name":"Surgery","level":1,"score":0.0},{"id":"https://openalex.org/C2776232967","wikidata":"https://www.wikidata.org/wiki/Q6743514","display_name":"Malignant pleural effusion","level":3,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2016-2133","doi":"https://doi.org/10.1158/1538-7445.am2016-2133","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2016-2133","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","doyens","jufo-3","ki-jl-3","medline","norway-2"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.504800021648407,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.5699999928474426,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2439017782","https://openalex.org/W2126298634","https://openalex.org/W3137415510","https://openalex.org/W2995958878","https://openalex.org/W2320440315","https://openalex.org/W3175790027","https://openalex.org/W2170144893","https://openalex.org/W2404235140","https://openalex.org/W2045309793","https://openalex.org/W2278530099"],"abstract_inverted_index":{"Abstract":[0],"The":[1],"enormous":[2],"success":[3],"of":[4,10,19,100,287,362,389,432,457,462],"kinase":[5,57,101,121,199,232,427],"inhibitors":[6,58,102,125,200,215,279],"in":[7,209,280,369],"the":[8,17,25,34,45,50,69,72,84,106,111,120,142,148,159,163,195,210,244,254,281,285,288,293,299,330,360,394,423,458,463],"treatment":[9],"cancer":[11],"is":[12,103,221,240,377],"being":[13],"rapidly":[14],"overshadowed":[15],"by":[16],"emergence":[18],"drug":[20],"resistance.":[21,167],"Drug-resistant":[22],"mutations":[23,156,220,297,429],"increase":[24],"kinases\u2019":[26],"binding":[27,54,246,290,301],"affinity":[28],"with":[29,44,105,119,158,235,266,296,438],"ATP,":[30],"shifting":[31],"them":[32,81],"to":[33,66,71,76,83,135,141,153,176,189,203,216,225,252],"active":[35,233],"conformation,":[36],"and/or":[37],"introduce":[38],"new":[39,214,218],"steric":[40,294],"hindrance":[41],"that":[42,114,239],"interferes":[43],"inhibitor":[46,160,381,437],"structural":[47],"motifs":[48,64],"outside":[49,298],"highly":[51],"conserved":[52,107,149],"ATP":[53,245,289,300],"boundary.":[55,302],"Most":[56],"are":[59,201],"oversized,":[60],"and":[61,94,178,184,191,277,313,320,339,344,353,382,402,444,451],"often":[62,126],"have":[63],"close":[65],"or":[67,131],"across":[68],"gatekeeper":[70,86],"hydrophobic":[73,117],"back":[74],"pocket":[75],"gain":[77],"high":[78],"potency,":[79],"rendering":[80],"vulnerable":[82],"clinical":[85,166],"mutations,":[87,392],"such":[88],"as":[89,154,248],"ALK":[90,170,180,309,398,447],"L1196M,":[91],"EGFR":[92],"T790M,":[93],"ABL":[95],"T315I.":[96],"Another":[97],"common":[98,174],"vulnerability":[99],"interaction":[104],"glycine":[108,150],"residue":[109],"at":[110,147],"hinge":[112],"C-terminal":[113],"forms":[115],"a":[116,132,173,236,249,262,267,378,386,434],"sandwich":[118,140],"\u03b21":[122],"sheet.":[123],"Kinase":[124],"use":[127],"an":[128],"aromatic":[129],"ring":[130],"flat":[133],"motif":[134,161],"go":[136],"through":[137],"this":[138],"narrow":[139],"solvent":[143,395],"exposure":[144],"area.":[145],"Alterations":[146],"commonly":[151],"referred":[152],"solvent-front":[155],"clash":[157],"inside":[162,243],"sandwich,":[164],"underlying":[165],"For":[168],"example,":[169],"G1202R":[171],"confers":[172],"resistance":[175,207,391,428],"crizotinib":[177,190],"other":[179],"inhibitors,":[181],"ROS1":[182,334,340,400,449],"G2032R":[183,341,401,450],"TRKA":[185,403,452],"G595R":[186,364,372],"render":[187],"resistances":[188],"entrectinib,":[192],"respectively.":[193],"Overall,":[194],"traditionally":[196],"designed,":[197],"oversized":[198],"destined":[202],"develop":[204],"many":[205],"different":[206],"profiles":[208],"clinic.":[211,282],"Continuously":[212],"introducing":[213],"overcome":[217,385],"evolving":[219,256],"becoming":[222],"increasingly":[223],"hard":[224],"sustain.":[226],"Here,":[227],"we":[228],"propose":[229],"targeting":[230,284],"resistance-driven":[231],"conformation":[234],"compact":[237],"molecule":[238],"completely":[241],"located":[242],"boundary":[247],"novel":[250,263,379],"strategy":[251],"tackle":[253],"ever":[255],"mutation":[257],"resistances.":[258],"We":[259],"designed":[260],"TPX-0005,":[261,433],"three-dimensional":[264],"macrocycle":[265],"much":[268],"smaller":[269],"size":[270],"(MW":[271],"<370)":[272],"than":[273],"current":[274],"ALK,":[275],"ROS1,":[276],"TRK":[278,345],"Efficiently":[283],"center":[286],"site":[291],"avoids":[292],"interference":[295],"As":[303],"expected,":[304],"TPX-0005":[305,324,357,376],"potently":[306,358],"inhibited":[307,359],"WT":[308,336],"(IC50":[310,365],"1.01":[311],"nM)":[312,319,368],"mutant":[314],"ALKs":[315],"including":[316,446],"ALKG1202R":[317],"(1.26":[318],"ALKL1196M":[321],"(1.08":[322],"nM).":[323,356],"demonstrated":[325],"even":[326],"stronger":[327],"potency":[328],"against":[329,442],"closely":[331],"related":[332],"kinases":[333],"(ROS1":[335],"0.07":[337],"nM":[338],"0.456":[342],"nM),":[343],"family":[346],"(TRKA":[347],"0.826":[348],"nM,":[349,352],"TRKB":[350],"0.052":[351],"TRKC":[354],"0.096":[355],"phosphorylation":[361],"LMNA-TRKA":[363,371],"<":[366],"1":[367],"NIH3T3":[370],"cells.":[373],"Taken":[374],"together,":[375],"ALK/ROS1/TRK":[380,436],"can":[383],"effectively":[384],"broad":[387,439],"spectrum":[388,440],"acquired":[390,425],"especially":[393],"front":[396],"mutants":[397,445],"G1202R,":[399,448],"G595R.":[404,453],"Citation":[405],"Format:":[406],"J.":[407],"Jean":[408],"Cui,":[409],"Evan":[410],"Rogers,":[411],"Dayong":[412],"Zhai,":[413],"Wei":[414],"Deng,":[415],"Zhongdong":[416],"Huang,":[417],"Jeffrey":[418],"Whitten,":[419],"Yishan":[420],"Li.":[421],"Ending":[422],"endless":[424],"tyrosine":[426],"\u2014":[430],"Design":[431],"multi-target":[435],"activity":[441],"wild-type":[443],"[abstract].":[454],"In:":[455],"Proceedings":[456],"107th":[459],"Annual":[460],"Meeting":[461],"American":[464],"Association":[465],"for":[466],"Cancer":[467,478],"Research;":[468],"2016":[469],"Apr":[470],"16-20;":[471],"New":[472],"Orleans,":[473],"LA.":[474],"Philadelphia":[475],"(PA):":[476],"AACR;":[477],"Res":[479],"2016;76(14":[480],"Suppl):Abstract":[481],"nr":[482],"2133.":[483]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":1},{"year":2018,"cited_by_count":1},{"year":2017,"cited_by_count":3}],"updated_date":"2026-10-02T10:15:12.560889","created_date":"2025-10-10T00:00:00"}